Key statistics
On Wednesday, Coherus BioSciences Inc (8C5:FRA) closed at 0.9362, 6.60% above its 52-week low of 0.8782, set on Sep 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.9404 |
---|---|
High | 0.9404 |
Low | 0.9362 |
Bid | 0.9104 |
Offer | 0.918 |
Previous close | 0.9606 |
Average volume | 3.34k |
---|---|
Shares outstanding | 115.21m |
Free float | 110.58m |
P/E (TTM) | -- |
Market cap | 119.82m USD |
EPS (TTM) | -0.4014 USD |
Data delayed at least 15 minutes, as of Oct 09 2024 14:42 BST.
More ▼
Announcements
- Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
- Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024
- Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
- Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
- Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference
- Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
- Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
- Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
- Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
More ▼